Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Chengdu Olymvax Biopharmaceuticals's average basic shares outstanding for the quarter that ended in Mar. 2026 was 405.2 Mil.
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Be Aware
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Chengdu Olymvax Biopharmaceuticals Shares Outstanding (Basic Average) Related Terms
Chengdu Olymvax Biopharmaceuticals Shares Outstanding (Basic Average) Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.
What does a Shares Outstanding (Basic Average) of 405.2 Mil mean?
Chengdu Olymvax Biopharmaceuticals (SHSE:688319) has a Shares Outstanding (Basic Average) of 405.2 Mil as of Mar. 2026. The average shares outstanding over two periods not accounting for dilutive securities like convertible bonds. View historical data on Chengdu Olymvax Biopharmaceuticals and its competitors.
Is Chengdu Olymvax Biopharmaceuticals' Shares Outstanding (Basic Average) too high?
Chengdu Olymvax Biopharmaceuticals' current Shares Outstanding (Basic Average) is 405.2 Mil. Overall, Chengdu Olymvax Biopharmaceuticals has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Chengdu Olymvax Biopharmaceuticals' Shares Outstanding (Basic Average) compare to VRTX and REGN?
Chengdu Olymvax Biopharmaceuticals' Shares Outstanding (Basic Average) of 405.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (Basic Average) for a Biotechnology company?
A good Shares Outstanding (Basic Average) depends on the Biotechnology industry context. However, Shares Outstanding (Basic Average) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (Basic Average) mean?
A high Shares Outstanding (Basic Average) can signal that a stock is expensive relative to its fundamentals. The average shares outstanding over two periods not accounting for dilutive securities like convertible bonds. View historical data on Chengdu Olymvax Biopharmaceuticals and its competitors. Chengdu Olymvax Biopharmaceuticals's current Shares Outstanding (Basic Average) is 405.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chengdu Olymvax Biopharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Chengdu Olymvax Biopharmaceuticals (SHSE:688319) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥23.13, compared to a current price of ¥27.08 — trading 17.1% above its estimated fair value. The current Shares Outstanding (Basic Average) is 405.2 Mil. Chengdu Olymvax Biopharmaceuticals' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (Basic Average) calculated?
Shares Outstanding (Basic Average) is calculated from a company's financial statements. For Chengdu Olymvax Biopharmaceuticals (SHSE:688319), the current Shares Outstanding (Basic Average) is 405.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Overvalued in 2026?
Based on GuruFocus' analysis, Chengdu Olymvax Biopharmaceuticals stock appears to be overvalued.
The current stock price of ¥27.08 is trading 17.1% above its estimated GF Value™ of ¥23.13.
GuruFocus considers Chengdu Olymvax Biopharmaceuticals to be Modestly Overvalued.
Key valuation signals for SHSE:688319:
Shares Outstanding (Basic Average): 405.2 Mil
GF Value™: ¥23.13 vs. price of ¥27.08 (17.1% above fair value)
No single metric tells the full story. See the SHSE:688319 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chengdu Olymvax Biopharmaceuticals Business Description
Chengdu Olymvax Biopharmaceuticals Inc is engaged in the research and development, production, and sales of human vaccines, focusing on innovative products.
73GF Score
Get the complete analysis for SHSE:688319
Shares Outstanding (Basic Average) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688319 has been successfully added to your 
